AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
-$1.07 today
- Market cap
- $1.40B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
Volume 0.57M
Average 0.76M
ANAB Interest Income
Income earned on cash, deposits, and investments held by the company.
AnaptysBio, Inc.NASDAQ: ANAB
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $2.65M fell 39.9% year over year, in line with the -40.2% change in trailing-twelve-month interest income. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +21.4% a year.
Context
- Interest income amounted to 5.8% of revenue in FY2025, down 15.9 pp from a year earlier.
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -39.9% holds above the trailing-twelve-month pace of -40.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 13.5M USD
- Year-over-year change
- -31.8%
- 4-year CAGR
- +136.6%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.5M | -31.8% |
| FY2024 | 2024-12-31 | 19.79M | +4.9% |
| FY2023 | 2023-12-31 | 18.87M | +150.0% |
| FY2022 | 2022-12-31 | 7.55M | +1651.7% |
| FY2021 | 2021-12-31 | 431K | — |
Interest Income vs competitors
How ANAB compares with its peers on the latest reported figures
- ANAB's LTM Mar 2026 interest income of $11.74M is the 4th highest of the 10 companies compared; the peer median is $5.01M.
- Its year-over-year change of -40.2% is the 6th highest of 9, against a peer median of -24.1%.
- Interest income amounts to 5.1% of revenue for ANAB, versus a peer median of 184.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $26.73M | +71.0% | +141.5% | 1404.0% | |
| LTM Jun 2026 | $23M | -24.6% | +78.8% | 21.9% | |
| LTM Sep 2026 | $20.29M | -13.4% | +49.5% | 285.9% | |
| LTM Mar 2026 | $11.74M | -40.2% | +21.4% | 5.1% | |
| LTM Mar 2026 | $6.99M | -14.1% | — | 83.5% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $5.01M | -23.7% | +66.4% | — |
| FY2025 | $2.27M | -49.1% | +13.2% | 3543.8% | |
| LTM Mar 2026 | $1.5M | -78.2% | -12.0% | 2.8% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$1.14M | -107.3% | +38.6% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ANAB) | $5.01M | -24.1% | +49.5% | 184.7% | |
Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.18M | 10.29M | 17.16M | 91.28M | 234.6M |
| Cost of Revenue | 98.5M | 88.8M | 132.28M | 163.84M | 2.42M |
| Gross Profit | (35.32M) | (78.51M) | (115.13M) | (72.56M) | 232.18M |
| Gross Margin | -55.9% | -763.2% | -671.0% | -79.5% | 99.0% |
| Research & Development | 98.5M | 88.8M | 139.62M | 163.84M | 135.97M |
| Selling, General & Admin | 21.49M | 36.64M | 41.95M | 42.39M | 50.74M |
| Operating Expenses | 21.49M | 36.64M | 49.29M | 42.39M | 184.28M |
| Depreciation & Amortization | 2.09M | 2.34M | 652K | 2.4M | 2.42M |
| EBITDA | (55.71M) | (105.26M) | (156.42M) | (92.74M) | 69.25M |
| EBITDA Margin | -88.2% | -1023.2% | -911.7% | -101.6% | 29.5% |
| Operating Income | (56.81M) | (115.15M) | (164.41M) | (114.95M) | 47.9M |
| Operating Margin | -89.9% | -1119.4% | -958.3% | -125.9% | 20.4% |
| Interest Income | 431K | 7.55M | 18.87M | 19.79M | 13.5M |
| Interest Expense | 1.45M | 21.11M | 18.08M | 50.09M | 79.89M |
| Other Income / Expenses | (982K) | (13.55M) | 788K | (30.28M) | (60.96M) |
| Income Before Tax | (57.8M) | (128.7M) | (163.62M) | (145.23M) | (13.07M) |
| Pre-Tax Margin | -91.5% | -1251.1% | -953.7% | -159.1% | -5.6% |
| Income Tax Expense | 0 | 24K | (4K) | 3K | 164K |
| Net Income | (57.8M) | (128.72M) | (163.62M) | (145.23M) | (13.23M) |
| Net Margin | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
| EPS (Basic) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| EPS (Diluted) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| Weighted Avg Shares | 27.43M | 28.17M | 26.92M | 28.38M | 27.79M |
| Weighted Avg Shares (Diluted) | 27.43M | 28.17M | 26.92M | 28.38M | 31.34M |
AnaptysBio, Inc.
NASDAQ:ANAB
Intrinsic Alpha fair value
Locked
Current Price
$47.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.